Patheon to make biologic drug for California firm; Plant in Fiji planned;

> Douglas Pharmaceuticals in Fiji has opened a new warehouse and intends to expand manufacturing. Report

> Valeant Pharmaceuticals ($VRX) is recalling 93,237 bottles of hypertension treater nifedipine extended-release tablets it manufactured for Teva ($TEVA) that dissolve too quickly. Notice

> The National Institutes of Health, which earlier this month closed a compounding facility after discovering fungal contamination, said Monday it has hired an expert on cGMP practices to help it resolve the facility's issues. Release

> Patheon has struck a deal to develop and manufacture a biologic drug for La Jolla, CA-based Inhibrx. Report

And Finally... Nordea Investment Management, the $240 billion asset manager, has written a letter to the 25 largest drugmakers raising concerns that the Indian companies to which they outsource work are polluting the water of local communities with wastewater from manufacturing. Report

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.